Breaking News

Scorpius Holdings Set to Launch First cGMP Mammalian Manufacturing Campaign

Highlights the expansion of its biomanufacturing capabilities in San Antonio, particularly in the field of mammalian cell culture production.

Author Image

By: Charlie Sternberg

Associate Editor

Scorpius Holdings Inc., an integrated contract development and manufacturing organization (CDMO), has announced that it expects to launch its first cGMP mammalian manufacturing campaign at its San Antonio manufacturing facility in the 3rd quarter of 2024. The commencement of mammalian cGMP campaigns marks a significant development as it opens new revenue streams for the company’s CDMO operations. Jeff Wolf, CEO of Scorpius, remarked, “I am extremely proud of what our team has accomplishe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters